Desmopressin Impurities

Desmopressin Related Compound

As a synthetic nonapeptide, desmopressin is sensitive to peptide-related synthetic challenges and degradation pathways, particularly under moisture, light, or acidic/basic conditions. Impurities must be strictly controlled due to the potent activity and parenteral use of the product, in compliance with ICH Q3A/B, Q6A, EP, and USP peptide monographs.

Types of Impurities in Desmopressin

Process-Related Impurities

• Deamidated peptides (e.g., loss of amide group from glutamine or asparagine)
• Truncated sequences (missing amino acids from N- or C-terminal)
• Epimerization (D/L isomerization of amino acids during synthesis)
• Protecting group residues or coupling by-products
• Residual solvents used during peptide synthesis or purification

Degradation Impurities

• Hydrolysis of peptide bonds under acidic/basic conditions
• Oxidation of methionine or cysteine residues
• Formation of cyclic peptides or aggregation products
• Photodegradation leading to discolored or inactive forms

Elemental Impurities

• Trace metals like palladium, copper, or iron from peptide coupling catalysts or equipment
• Regulated under ICH Q3D for injectable and nasal formulations

Analytical Techniques for Impurity Detection

• Reverse-phase HPLC (RP-HPLC) – for peptide mapping, assay, and related substances
• LC-MS/MS – for identification and structural elucidation of impurities
• Capillary Electrophoresis (CE) – for size and charge-related variants
• GC – for detection of residual solvents
• ICP-MS – for elemental impurities
• Stability testing under ICH conditions – to monitor degradation over time

FAQ